Eisai Co., Ltd. Skip Navigation Top menu Japanese | English
| Sitemap |
   Home > about Eisai > News Releases
Side menu
Message from the President
Corporate Philosophy
Corporate Governance
hhc & Compliance
Corporate Information
Japan Business Sites
Research & Development
Production Logistics
Marketing
News Releaseselected

Main contents
    News Release
each year's index
2010  |  2009  |  2008  |  2007  |  2006  |  2005  |  2004  |  2003  |  2002  |  2001  |  2000  |  1999  | 
1998  |  1997  |  1996  |

Information in the news releases is current on the date of the announcement, but is subject to change without prior notice.
2008 Release
  December 15, 2008
FDA Approves Sedative-Hypnotic Agent LUSEDRA™ Injection


  November 17, 2008
FDA Approves BANZEL™ (rufinamide) as Adjunctive Treatment for Lennox-Gastaut Syndrome


  November 11, 2008
Eisai Completes Alliance Agreement with TorreyPines Therapeutics for Genetic Research Programs to Discover Genes Associated with LOAD
-New Agreement Signed for Eisai to Purchase Research Assets-



  October 29, 2008
HOUSE OF LORDS REFUSES TO HEAR NICE'S APPEAL


  October 16, 2008
FDA Grants Full Approval to ONTAK® (denileukin diftitox) For Use in Patients with Cutaneous T-Cell Lymphoma (CTCL)


  October 8, 2008
Eisai Introduces “Chocola BB® Drink bit”, New Pharmaceutical Drink for Acne and Skin Care


  September 3, 2008
Eisai Introduces “Hotmin®” for Improving Peripheral Blood Circulation


  August 24, 2008
FDA Approves ALOXI® (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting


  August 18, 2008
SymBio Pharmaceuticals and Eisai Sign License Agreement for bendamustine hydrochloride (SyB L-0501)


  July 31, 2008
Continuation of Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders


  July 30, 2008
Eisai China Inc. Signs License Agreement in China for alpha-Lipon 300 STADA® for Diabetic Neuropathic Pain


  July 26, 2008
Eisai Receives Action Letter on Fospropofol Disodium Injection for Sedation in Diagnostic or Therapeutic Procedures -FDA's Not Approvable Letter Outlines Pathway to Potential Approval-


  July 22, 2008
U.S. FEDERAL CIRCUIT COURT OF APPEALS FULLY UPHOLDS EISAI'S FAVORABLE RULING IN ACIPHEX® PATENT INFRINGEMENT LAWSUIT AGAINST TEVA PHARMACEUTICALS AND DR. REDDY'S LABORATORIES


  July 16, 2008
Antiosteoporotic drugs “Actonel® 17.5 mg tablets” and “Benet® 17.5 mg tablets” received approval for additional indication in patients with Paget's disease of bone: Both come in new packages.


  July 9, 2008
ALOXI® (PALONOSETRON HCL) INJECTION AVAILABLE FOR PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING


  July 7, 2008
Notice on Determination of Details of Stock Options (Stock Acquisition Rights) to be Allocated


  July 1, 2008
EISAI PROVIDES PRELIMINARY EFFICACY UPDATE ON EORTC PHASE III TRIAL OF DACOGEN® VERSUS SUPPORTIVE CARE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES


  July 1, 2008
Proton Pump Inhibitor ACIPHEX® 20 mg Receives Approval for Short-Term Treatment of GERD in Adolescents in United States


  June 20, 2008
Notice on Allocation of Stock Options (Stock Acquisition Rights)


  June 19, 2008
Transfer of Subsidiary Stock


  June 17, 2008
HUMIRA® Subcutaneous Injection 40mg Syringe 0.8mL Now Available for the Treatment of Rheumatoid Arthritis


  May 29, 2008
Notification with Respect to Issuance of Unsecured Straight Bonds


  May 29, 2008
Termination of marketing alliance of Breathe Right® nasal strips


  May 22, 2008
NON-IONIC CONTRAST AGENTS, IOMERON® 350 AND IOMERON® 350 SYRINGE, RECEIVE APPROVAL FOR USE IN DYNAMIC CT LIVER IMAGING


  May 16, 2008
E7389 Demonstrated Anti-tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer


  May 16, 2008
Eisai Presents 16 Papers Accepted for ASCO Annual Meeting Reporting the Latest Results from its Oncology Research


  May 14, 2008
Notice on New Stock Issuance in the Form of Stock Options


  May 12, 2008
Distribution of Ethical Drugs Bufferin 81mg Tablets & Bufferin 330mg Tablets


  May 9, 2008
COURT OF APPEAL MAKES DECISION FOLLOWING RULING THAT NICE PROCESS ON ANTI-DEMENTIA MEDICINES UNFAIR


  May 8, 2008
FDA ADVISORY COMMITTEE VOTES IN FAVOR OF APPROVAL OF FOSPROPOFOL DISODIUM INJECTION FOR SEDATION


  May 7, 2008
Eisai Establishes a New Subsidiary in China for Marketing Support and Maintenance of Pharmaceutical Manufacturing Machinery


  May 1, 2008
Eisai Gained Favourable Ruling by Court of Appeal, as NICE Process for Developing Guidance on Anti-dementia Medicines Ruled Unfair


  April 24, 2008
Eisai Introduces “Chocola BB® Royal 2” Vitamin B2 Drink for Extreme Fatigue  A New Drink with Amino Acids and Reduced Calories


  April 21, 2008
Notice of Revised Business Forecast for Fiscal Year Ended March 31, 2008, as a Result of Acquisition of MGI PHARMA, INC.


  April 16, 2008
European Regulatory Agency Grants Orphan Status to Morphotek®'s FARLETUZUMAB (MORAb-003) and MORAb-009


  April 16, 2008
HUMIRA® received approval for the treatment of rheumatoid arthritis in Japan


  April 11, 2008
Status of the E2007 (perampanel) Development Program- Termination of Parkinson's Disease Clinical Development and Focus on Neuropathic Pain and Epilepsy Indications -


  April 3, 2008
Eisai to Resume Clinical Study to Evaluate E2012 as a Potential Next Generation Alzheimer's Disease Treatment


  March 29, 2008
Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept® Patent Infringement Lawsuit against Teva Pharmaceuticals


  March 28, 2008
Notice Concerning Shelf Registration for Issuance of Stock Options


  March 28, 2008
Notice Concerning Shelf Registration for Issuance of Straight Bonds


  March 14, 2008
Eisai Submits Application for Aricept® Oral Jelly Formulation in Japan


  March 13, 2008
Eisai and Sanko Junyaku introduce New KL-6 Test Kits for LUMIPULS® Systems for Detecting Marker of Interstitial Pneumonia


  March 12, 2008
M’s Science and Eisai Sign Option Agreement for Sigma Agonist SA4503


  March 3, 2008
FDA APPROVES ALOXI® (PALONOSETRON HCL) INJECTION FOR PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING


  March 3, 2008
Vasolan® (Ischaemic Heart Disease Treatment) Received Approval for Atrial Fibrillation/Flutter and Paroxysmal Supraventricular Tachycardia


  March 1, 2008
FDA Grants Priority Review for ACIPHEX® sNDA for Short-Term Treatment of GERD in Adolescents


  February 28, 2008
Eisai Launches New CHOCOLA BB Product Lines CHOCOLA® BB Lucent C and CHOCOLA® BB Lucent Cream for Blemishes and Brown Spots on Skin


  February 13, 2008
Eisai and Accenture launch Clinical Data Management in India under global outsourcing agreement


  February 1, 2008
Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application


  February 1, 2008
Eisai Decides Additional Study for Pariet® for New Indication of Non-Erosive Gastro-Esophageal Reflux Disease in Japan


  January 29, 2008
Abbott and Eisai Finalize License Agreement in Japan for Additional Indications for Adalimumab, The Only Fully Human Monoclonal anti-TNF-alpha Antibody


  January 29, 2008
EISAI COMPLETES ACQUISITION OF MGI PHARMA


  January 28, 2008
Abbott and Eisai Announce Changes in the Sales Scheme in Japan for Adalimumab, A Fully Human Monoclonal Anti-TNF-alpha Antibody


  January 23, 2008
EISAI ANNOUNCES SATISFACTION OF CONDITIONS TO TENDER OFFER FOR MGI PHARMA SHARES


  Page Top    
Bottom menu
   Privacy Policy  |   Terms of Use  |   Accessibility
Copyright(C) Eisai Co., Ltd All right reserved.